In a review [1] published in this journal in 2014 we updated the role of statin 
treatment in patients with type 2 diabetes mellitus (T2DM). This is an important 
topic because the prevalence of T2DM is increasing and this disease is 
associated with a high risk of cardiovascular disease (CVD) as well as 
microvascular complications [1]. The relationship between T2DM and statins is 
further complicated since these drugs can cause new onset diabetes (NOD) 
although there is an overall benefit in terms of preventing vascular events [1, 
2]. The cost implications of T2DM in terms of quality of life as well as 
providing healthcare are obvious. This is a brief update of our earlier review 
[1] based on recently published data.